Horizon Therapeutics briefly ticked lower on report of FTC 2nd request in Amgen deal
hapabapa


Horizon Therapeutics (NASDAQ:HZNP) briefly ticked down on a report that Amgen (NASDAQ:AMGN) received a so-called "2nd request" from the Federal Trade Commission in regards to its planned almost $28 billion acquisition.
Horizon (HZNP) and Amgen (AMGN) are said to have received the request for a more in-depth probe from the FTC as a deadline for the regulatory agency expired, according to trader, who cited an CTFN report that's circulating.

Amgen (AMGN) agreed to acquire rare-disease-focused Horizon Therapeutics for $116.50 per share in cash last month, valuing the Ireland-based biotech at nearly $27.8 billion.

The FTC request comes as Sen. Elizabeth Warren (D-MA) on Wednesday wrote a letter to the the antitrust regulator about her concerns with the transaction. 

Amgen (AMGN) is scheduled to report Q4 results after the close on Tuesday and investors may get an update on Horizon (HZNP) on the company's conference call. Horizon is scheduled to report Q4 results on March 1.